★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★Open research. Global perspectives.
editor@theamericanjournals.comPublisher Home ↗
Medical Science OPEN ACCESS

THE CONTRIBUTION OF NON-ALCOHOLIC FATTY LIVER DISEASE TO THE PROGRESSION OF ATHEROSCLEROSIS

S.I. Sadikova
Associate Professor, Department Of Internal Medicine, Family Medicine No. 2, Tashkent Medical Academy, Tashkent, Uzbekistan
N. S.- Khodjaeva
Doctor Of The Highest Category Of Ultrasound Diagnostics At The Akfa University Clinicmedline, Tashkent, Uzbekistan
DOI Crossref DOI 10.37547/TAJMSPR/Volume06Issue06-02
tajmspr 2024
VOL. 6 / NO. 06 JUNE
FULL TEXT PP. 8-17
DOWNLOAD PDF

View all articles in this issue ↗

VOLUME 6
ISSUE 06
YEAR 2024
PAGES 8-17
RESEARCH OVERVIEW

Abstract

In the context of insulin resistance syndrome, which encompasses changes in lipid and carbohydrate metabolism, liver-related issues are now being closely examined alongside cardiovascular diseases. Our research aimed to evaluate the predictive importance of non-alcoholic fatty liver disease (NAFLD) for identifying the likelihood of early atherosclerotic alterations in the carotid arteries. We discovered a connection between NAFLD and initial signs of atherosclerosis. By ranking prognostic factors that affect changes in the carotid artery wall, we've been able to develop a method for estimating individual atherosclerosis risk in people who are otherwise healthy. The practical value of our findings underscores the need for in-depth evaluation of individuals with NAFLD to identify risk factors that may contribute to the advancement of both liver and cardiovascular diseases.

RESEARCH TOPICS

Keywords

Non-alcoholic fatty liver disease insulin resistance atherosclerosis

Downloads

Download data is not yet available.
SOURCES & SCHOLARSHIP

References

  1. Bacon, B. R., &Farahvash, M. J. (1994). Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology, 107, 1103–1109.
  2. Browning, J. D., Szczepaniak, L. S., Dobbins, R., et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology, 40(1), 1387–1395.
  3. De Alwis, N. M., & Day, C. P. (2008). Non-alcoholic fatty liver disease: The mist gradually clears. Journal of Hepatology, 48(Suppl. 1), 104–112.
  4. Drapkina, O. M., Deeva, T. A., &Ivashkin, V. T. (2015). Assessment of degree of endothelial function and apoptosis in patients with metabolic syndrome and nonalcoholic fatty liver disease. TerapevticheskiiArkhiv, 87(5), 7683.
  5. Korneeva, O. N., Drapkina, O. M., Bueverov, S. A., &Ivashkin, V. T. (2005). Nonalcoholic fatty liver disease as a manifestation of the metabolic syndrome. KlinicheskiePerspektivyGastroenterologiiiGepatologii.
  6. Ivashkin, V. T., Drapkina, O. M., Maiev, I. V., et al. (2015). The prevalence of nonalcoholic fatty liver disease in patients of outpatient practice in the Russian Federation: Results of the DIREG 2 trial. RossiyskiyZhurnalGastroenterologii, Gepatologii, Koloproktologii, 6, 31–41.
  7. Roden, M. (2006). Mechanisms of disease: Hepatic steatosis in type 2 diabetes - Pathogenesis and clinical relevance. Nature Clinical Practice Endocrinology & Metabolism, 2(6), 335–348.
  8. Perez-Aguilar, F. (2005). Etiopathogenesis of non-alcoholic steatohepatitis. Gastroenterologia y Hepatologia, 28(7), 396–406.
  9. Lonardo, A. (2005). Review article: Hepatic steatosis and insulin resistance. Alimentary Pharmacology & Therapeutics, 22(2), 64–70.
  10. Lazebnik, B. L., Zvenigorodskaia, L. A., &Egorova, E. G. (2005). Metabolic syndrome from the gastroenterologist's perspective. RMJ, 13(26), 1706–1712. [In Russian]
  11. Leon, A. A., Paul, A., & Lindor, K. D. (2005). Nonalcoholic fatty liver disease. CMAJ, 29, 172–178.
  12. Chalasani, N., Younossi, Z., Lavine, J. E., et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55, 2005–2023.
  13. Salvi, P., Ruffini, R., Agnoletti, D., et al. (2010). Increased arterial stiffness in nonalcoholic fatty liver disease: The Cardio-GOOSE study. Journal of Hypertension, 28(8), 1699–1707.
  14. Ramilli, S., Pretolani, S., Muscari, A., et al. (2009). Carotid lesions in outpatients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 15(38), 4770–4774.
  15. Yoneda, M., Mawatari, H., Fujita, K., et al. (2007). High-sensitivity C-reactive protein is an independent clinical feature of non-alcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. Journal of Gastroenterology, 42, 573–582.
  16. Drapkina, O. M., Bueverova, E. L., &Ivashkin, V. T. (2010). Atherogenic dyslipidemia and liver. AteroskleroziDislipidemii, 1, 25–30.
  17. Ivashkin, V. T. (2010). Nuclear receptors and liver disease. Part 2-I. RossiyskiyZhurnalGastroenterologii, Gepatologii, Koloproktologii, 4, 7–15.
  18. Korneeva, O. N., &Drapkina, O. M. (2012). How to avoid the appointment of statin hepatotoxicity in patients with obesity and related liver disease? Focus on a combination of ursodeoxycholic acid and atorvastatin. KardiovaskulyarnayaTerapiyaiProfilaktika, 11(6), 81–84.
  19. Martsevich, S. Y., Kutishenko, N. P., Drozdova, L. Y., et al. (2014). Study of ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with diseases of the liver, gall bladder and/or biliary tract (the RAKURS study). Rational Pharmacotherapy in Cardiology, 10(2), 147–152.
  20. Kim, B. J., Kim, N. H., Kim, B. S., & Kang, J. H. (2012). The association between nonalcoholic fatty liver disease, metabolic syndrome, and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology, 123, 54–61.
  21. Lee, Y. J., Shim, J. Y., Moon, B. S., et al. (2012). The relationship between arterial stiffness and nonalcoholic fatty liver disease. Digestive Diseases and Sciences, 57, 196–203.
  22. Zyatenkova, E. V., Drapkina, O. M., &Ivashkin, V. (2014). Characteristics of vessels wall, myocardium, and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome. Endoscopic Ultrasound, 3(Suppl 1), S1–S2.